197 related articles for article (PubMed ID: 30838834)
21. An Optimized Anti-infliximab Bridging Enzyme-linked Immunosorbent Assay for Harmonization of Anti-infliximab Antibody Titers in Patients with Inflammatory Bowel Diseases.
Van Stappen T; Billiet T; Vande Casteele N; Compernolle G; Brouwers E; Vermeire S; Gils A
Inflamm Bowel Dis; 2015 Sep; 21(9):2172-7. PubMed ID: 26284296
[TBL] [Abstract][Full Text] [Related]
22. Comparison of two ELISA versions for infliximab serum levels in patients diagnosed with ankylosing spondylitis.
Hernández-Flórez D; Valor L; de la Torre I; Nieto JC; Martínez-Estupiñán L; González C; López-Longo FJ; Monteagudo I; Garrido J; Naredo E; Carreño L
Rheumatol Int; 2015 Jun; 35(6):1021-5. PubMed ID: 25410014
[TBL] [Abstract][Full Text] [Related]
23. Comparative study of a point-of-care test and an enzyme-linked immunosorbent assay (ELISA) for infliximab levels.
Thunberg J; Grännö O; Bergemalm D; Eriksson C; Visuri I; Eberhardson M; Halfvarson J
Scand J Gastroenterol; 2024; 59(2):150-155. PubMed ID: 37882356
[TBL] [Abstract][Full Text] [Related]
24. Comparison of three commercially available ELISA assays for anti-infliximab antibodies.
West TA; Sam M; Toong C
Pathology; 2021 Jun; 53(4):508-514. PubMed ID: 33272693
[TBL] [Abstract][Full Text] [Related]
25. Infliximab trough levels are decreasing over time in patients with inflammatory bowel disease on maintenance treatment with infliximab.
Orfanoudaki E; Gazouli M; Foteinogiannopoulou K; Theodoraki E; Legaki E; Romanos I; Mouzas I; Koutroubakis IE
Eur J Gastroenterol Hepatol; 2019 Feb; 31(2):187-191. PubMed ID: 30543573
[TBL] [Abstract][Full Text] [Related]
26. An in vitro comparison of four different immunoassays for the monitoring of Infliximab biosimilars drug levels.
Neveu B; Kunst A; Prosser C; Robitaille R
Clin Biochem; 2020 Apr; 78():58-62. PubMed ID: 31982376
[TBL] [Abstract][Full Text] [Related]
27. Viability of a Serum Infliximab Concentration-Detecting Reagent as a Qualitative Assay for an Infliximab Biosimilar.
Inagaki T; Isesaki T; Kawana K; Funakoshi R
Biol Pharm Bull; 2021; 44(9):1272-1279. PubMed ID: 34471055
[TBL] [Abstract][Full Text] [Related]
28. Verification between Original and Biosimilar Therapeutic Antibody Infliximab Using nSMOL Coupled LC-MS Bioanalysis in Human Serum.
Iwamoto N; Yokoyama K; Takanashi M; Yonezawa A; Matsubara K; Shimada T
Curr Pharm Biotechnol; 2018; 19(6):495-505. PubMed ID: 29968534
[TBL] [Abstract][Full Text] [Related]
29. Surface plasmon resonance assays for the therapeutic drug monitoring of infliximab indicate clinical relevance of anti-infliximab antibody binding properties.
Grasmeier MK; Weber S; Treiber M; Thaler MA; Luppa PB
Clin Chem Lab Med; 2023 Jun; 61(7):1255-1265. PubMed ID: 36753693
[TBL] [Abstract][Full Text] [Related]
30. [Comparison of two kits of anti-infliximab antibodies plasmatic measurement].
Charfi R; Mahmoud I; Ben Salem F; Moalla M; Bouden S; Sfar I; Saïdane O; Klouz A; Daghfous R; Gorgi Y; Abdelmoula L; Trabelsi S
Ann Biol Clin (Paris); 2019 Aug; 77(4):453-458. PubMed ID: 31418707
[TBL] [Abstract][Full Text] [Related]
31. Clinical efficacy of infliximab level and anti-infliximab antibody measurement in patients with inflammatory bowel disease: An audit.
Dave MB; Dherai AJ; Desai DC; Keny BG; Shetty DN; Kulkarni S; Peddy K; Ashavaid TF
Indian J Gastroenterol; 2020 Oct; 39(5):426-434. PubMed ID: 33118097
[TBL] [Abstract][Full Text] [Related]
32. Clinical Use of Infliximab Trough Levels and Antibodies to Infliximab in Pediatric Patients With Inflammatory Bowel Disease.
Merras-Salmio L; Kolho KL
J Pediatr Gastroenterol Nutr; 2017 Feb; 64(2):272-278. PubMed ID: 27149256
[TBL] [Abstract][Full Text] [Related]
33. Infliximab Trough Levels at Induction to Predict Treatment Failure During Maintenance.
Liefferinckx C; Minsart C; Toubeau JF; Cremer A; Amininejad L; Quertinmont E; Devière J; Gils A; van Gossum A; Franchimont D
Inflamm Bowel Dis; 2017 Aug; 23(8):1371-1381. PubMed ID: 28498153
[TBL] [Abstract][Full Text] [Related]
34. Infliximab quantitation in human plasma by liquid chromatography-tandem mass spectrometry: towards a standardization of the methods?
Jourdil JF; Lebert D; Gautier-Veyret E; Lemaitre F; Bonaz B; Picard G; Tonini J; Stanke-Labesque F
Anal Bioanal Chem; 2017 Feb; 409(5):1195-1205. PubMed ID: 27826630
[TBL] [Abstract][Full Text] [Related]
35. Clinical utility of antihuman lambda chain-based enzyme-linked immunosorbent assay (ELISA) versus double antigen ELISA for the detection of anti-infliximab antibodies.
Kopylov U; Mazor Y; Yavzori M; Fudim E; Katz L; Coscas D; Picard O; Chowers Y; Eliakim R; Ben-Horin S
Inflamm Bowel Dis; 2012 Sep; 18(9):1628-33. PubMed ID: 22038899
[TBL] [Abstract][Full Text] [Related]
36. Therapeutic Drug Monitoring to Guide Infliximab Dose Adjustment is Associated with Better Endoscopic Outcomes than Clinical Decision Making Alone in Active Inflammatory Bowel Disease.
Kelly OB; Donnell SO; Stempak JM; Steinhart AH; Silverberg MS
Inflamm Bowel Dis; 2017 Jul; 23(7):1202-1209. PubMed ID: 28498155
[TBL] [Abstract][Full Text] [Related]
37. Therapeutic Drug Monitoring of Anti-TNFα Inhibitors: A Matter of Cut-Off Ranges.
Cheli S; Savino D; Penagini F; Zuccotti G; Zuin G; Clementi E; Cattaneo D
Pharmaceutics; 2023 Jun; 15(7):. PubMed ID: 37514022
[TBL] [Abstract][Full Text] [Related]
38. Comparative Evaluation of Four Commercially Available Immunoassays for Therapeutic Drug Monitoring of Infliximab and Adalimumab.
Rissel F; Cazaubon Y; Saffar S; Altwegg R; Artasone M; Lozano C; Vincent T; Jentzer A
Int J Mol Sci; 2023 Jun; 24(12):. PubMed ID: 37373525
[TBL] [Abstract][Full Text] [Related]
39. Impact of infliximab therapeutic drug level monitoring on outcomes of patients with inflammatory bowel disease: A real-world experience from a Middle Eastern cohort.
Azzam N; Aljebreen A; Alharbi O; Charabaty A; Alanazi M; Alkuwaykibi N; Alfaraidi J; Bashamil A; Almansour T; Almadi M
Arab J Gastroenterol; 2021 Mar; 22(1):66-72. PubMed ID: 33632623
[TBL] [Abstract][Full Text] [Related]
40. The Utility of Infliximab Therapeutic Drug Monitoring among Patients with Inflammatory Bowel Disease and Concerns for Loss of Response: A Retrospective Analysis of a Real-World Experience.
Mitchell RA; Shuster C; Shahidi N; Galorport C; DeMarco ML; Rosenfeld G; Enns RA; Bressler B
Can J Gastroenterol Hepatol; 2016; 2016():5203898. PubMed ID: 27957480
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
